Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients?

36Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Regulatory agencies in North America and Europe recently re-evaluated the safety of metoclopramide. This re-evaluation resulted in recommendations and restrictions in order to minimise the risk of neurological and other adverse reactions associated with the use of metoclopramide. In the ICU, off-label prescription of metoclopramide is common. We have reviewed the evidence for safety, effectiveness and dosing of metoclopramide in critically ill patients. Furthermore, tachyphylaxis is addressed and alternatives are summarised. Finally, recommendations are presented not to abandon use of metoclopramide in ICU patients, because metoclopramide is considered effective in enhancing gastric emptying and facilitating early enteral nutrition.

Cite

CITATION STYLE

APA

van der Meer, Y. G., Venhuizen, W. A., Heyland, D. K., & van Zanten, A. R. H. (2014). Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? Critical Care, 18(5). https://doi.org/10.1186/s13054-014-0502-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free